Kingdon Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Kingdon Capital Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-348,753	Closed	-$2.49M	–	169
2015 Q1	$2.49M	Sell	348,753 -50,000	-13%	-$345K	0.11%	133
2014 Q4	$2.97M	Sell	398,753 -225,000	-36%	-$1.91M	0.13%	124
2014 Q3	$5.77M	Sell	623,753 -120,750	-16%	-$1.63M	0.26%	97
2014 Q2	$13.9M	Buy	744,503 +204,853	+38%	+$3.48M	0.53%	55
2014 Q1	$9.96M	Sell	539,650 -60,350	-10%	-$1.15M	0.51%	63
2013 Q4	$6.68M	Buy	+600,000	New	+$7.15M	0.31%	103

Other funds holding KIN

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Kingdon Capital Management's KIN Position: Q2 2015 in Review

Kingdon Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2015, closing a stake of 348,753 shares — an estimated $2.49M sold.

Kingdon Capital Management first reported a position in KIN in Q4 2013 and held it in 6 quarters. The position peaked at $13.9M in Q2 2014. 57 funds tracked by Wall St. Rank hold KIN as of Q2 2015.

Kingdon Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2015 after selling out during the quarter.
Kingdon Capital Management sold 348,753 Kindred Biosciences, Inc. shares in Q2 2015, an estimated $2.49M.
Kingdon Capital Management first reported a position in Kindred Biosciences, Inc. in Q4 2013 and held it in 6 quarters.
Kingdon Capital Management's Kindred Biosciences, Inc. position peaked at $13.9M in Q2 2014.
57 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2015.

Based on Kingdon Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.